Pill bottle-themed Lucite tombstone marking the acquisition of a royalty interest in worldwide sales of Xenpozyme. Xenpozyme has been developed and approved as a treatment for acid sphingomyelinase deficiency (ASMD). (22AKL627)
Pill bottle-themed Lucite tombstone marking the acquisition of a royalty interest in worldwide sales of Xenpozyme. Xenpozyme has been developed and approved as a treatment for acid sphingomyelinase deficiency (ASMD). (22AKL627)
Crystal financial tombstone celebrating Series A funding for Lokavant. Based in New York, Lokavant provides a centralized data repository for clinical drug trials. (23AKL083)
Crystal financial tombstone marking a private placement by Midatech Pharma. The drug delivery technology firm is based in the UK. (23AJH028)
Crystal deal tombstone marking a follow-on offering by life sciences company Intelligent Bio Solutions The design incorporates the firm’s drug screening cartridge. (23AJH030)
Crystal commemorative marking a licensing and commercialization agreement between Corbus Pharmaceuticals and CSPC Pharmaceutical Group. The agreement centers on a potential treatment for tumors associated with lung, breast, and prostate cancers. (23AZH089)
Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Diamond-shaped crystal deal toy commemorating a follow-on stock offering by Swiss biotech firm Oculis. (23AKL262)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
